The BROOKLYN randomized, double-blind, placebo-controlled phase III clinical trial enrolled 354 patients with heterozygous familial hypercholesterolemia (HeFH) who had LDL cholesterol levels above 70 mg/dL despite maximally tolerated lipid-lowering therapy.[1][2][5] Patients were randomized 2:1 to obicetrapib 10 mg or placebo as an add-on to their treatment for 52 weeks.[1][2][5] The study met the primary objective of reducing LDL cholesterol by 36.3% at day 84 versus placebo (p < 0.0001).[1][2][5] This effect was sustained at 41.5% reduction at day 365.[1][2] Obicetrapib also significantly reduced other biomarkers, including HDL cholesterol, non-HDL cholesterol, lipoprotein(a), and apolipoprotein B.[1][3] The treatment was well tolerated, with a similar incidence of adverse events and discontinuations to placebo.[1][5] More than half of the patients achieved an LDL cholesterol level below 70 mg/dL.[2]